Phase III clinical trials now average 3.6 million datapoints, a threefold increase over the last decade. 1 The Certara Pinnacle 21 platform is designed to solve the data standardization challenges of ...

UBS reaffirmed its Buy rating and $105 target for Merck, brushing off investor pessimism about the pharmaceutical giant’s ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData. MSD’s data arrived on the same day that Germany-based Merck KGaA, also ...

MSD will supply Keytruda free of charge for this trial. Hanmi Pharmaceutical's HM16390 is a newly designed drug candidate that regulates IL-2, a protein that modulates the immune response in our body.

MSD – known as Merck & Co in the US and Canada – has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its adult-specific pneumococcal vaccine Capvaxive. The ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly ...

India Business News: HYDERABAD: Integrated digital health startup EkinCare on Tuesday said it raised a strategic, undisclosed investment led by global healthcare giant MSD.

MSD reported first-quarter sales of $15.5 billion (approximately 22.24 trillion won), an increase of about 8% compared to the same period last year.

Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing oral formulations of Merck’s peptides, with the deal worth over $493m. The ...

In March, Merck and Jiangsu Hengrui Pharmaceuticals Co., Ltd entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein (a), or Lp (a), inhibitor ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N) said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October ...